Unknown

Dataset Information

0

Dual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer.


ABSTRACT: Resistance to androgen-receptor (AR) directed therapies is, among other factors, associated with Myc transcription factors that are involved in development and progression of many cancers. Overexpression of N-Myc protein in prostate cancer (PCa) leads to its transformation to advanced neuroendocrine prostate cancer (NEPC) that currently has no approved treatments. N-Myc has a short half-life but acts as an NEPC stimulator when it is stabilized by forming a protective complex with Aurora A kinase (AURKA). Therefore, dual-inhibition of N-Myc and AURKA would be an attractive therapeutic avenue for NEPC. Following our computer-aided drug discovery approach, compounds exhibiting potent N-Myc specific inhibition and strong anti-proliferative activity against several N-Myc driven cell lines, were identified. Thereafter, we have developed dual inhibitors of N-Myc and AURKA through structure-based drug design approach by merging our novel N-Myc specific chemical scaffolds with fragments of known AURKA inhibitors. Favorable binding modes of the designed compounds to both N-Myc and AURKA target sites have been predicted by docking. A promising lead compound, 70812, demonstrated low-micromolar potency against both N-Myc and AURKA in vitro assays and effectively suppressed NEPC cell growth.

SUBMITTER: Ton AT 

PROVIDER: S-EPMC7663809 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Dual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer.

Ton Anh-Tien AT   Singh Kriti K   Morin Hélène H   Ban Fuqiang F   Leblanc Eric E   Lee Joseph J   Lallous Nada N   Cherkasov Artem A  

International journal of molecular sciences 20201105 21


Resistance to androgen-receptor (AR) directed therapies is, among other factors, associated with Myc transcription factors that are involved in development and progression of many cancers. Overexpression of N-Myc protein in prostate cancer (PCa) leads to its transformation to advanced neuroendocrine prostate cancer (NEPC) that currently has no approved treatments. N-Myc has a short half-life but acts as an NEPC stimulator when it is stabilized by forming a protective complex with Aurora A kinase  ...[more]

Similar Datasets

| S-EPMC10310825 | biostudies-literature
| S-EPMC8910697 | biostudies-literature
| S-EPMC4829466 | biostudies-literature
| S-EPMC5676429 | biostudies-literature
| S-EPMC3556934 | biostudies-literature
| S-EPMC3400487 | biostudies-other
| S-EPMC5540451 | biostudies-literature
| S-EPMC8289743 | biostudies-literature
| S-EPMC3047603 | biostudies-other
| S-EPMC2711630 | biostudies-literature